Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Argenx Nears Phase III In Myasthenia Gravis

Executive Summary

The reporting of positive topline Phase II results for a modified antibody fragment, efgartigimod, in myasthenia gravis by the Netherlands-based antibody-engineering biotech, argenx, has added to a growing list of new therapeutic approaches for the disorder.

Advertisement

Related Content

Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Alexion Seizes On New Soliris Indication, Business Development For Growth

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel